⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIV News
Roivant Sciences Ltd. Common Shares
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
globenewswire.com
ROIV
ROIVW
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
globenewswire.com
IMVT
ROIV
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
globenewswire.com
ROIV
Roivios Reports Promising Results from First-in-Human Trial of JuxtaFlow® Renal Assist Device
prnewswire.com
ROIV
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
globenewswire.com
ROIV
PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets
globenewswire.com
ROIV
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
globenewswire.com
ROIV
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
globenewswire.com
ROIV